Marshall Wace
PRME icon

Marshall Wace’s Prime Medicine PRME Stock Holding History

Marshall Wace’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$494K Buy
+141,957
New +$540K ﹤0.01% 2463

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Marshall Wace's PRME Position: Q1 2026 in Review

Marshall Wace opened a new position in Prime Medicine (PRME) in Q1 2026: 141,957 shares worth $494K. The stake represents ﹤0.01% of the portfolio and ranks #2463 among its holdings.

192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Marshall Wace held 141,957 shares of Prime Medicine worth $494K as of Q1 2026.
  • Prime Medicine was a new Marshall Wace position in Q1 2026.
  • Prime Medicine made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2463 holding.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.